ヘイドロキシメチルグルタリル共酵素であるセリバスタチンは,リドゥクタゼ阻害剤であり,3日以内に高齢の糖尿病患者の内皮機能を改善します

T Tsunekawa¹, T Hayashi, H Kano

¹Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Circulation

|July 27, 2001

まとめ

短期的なセリバスタチンは,老年糖尿病患者の内皮機能を改善し,酸化窒素を増やし,酸化ストレスを下げ,脂質レベルを変えることなく改善しました. これは,抗動脈硬化作用の潜在的な利点を示唆しています.

科学分野:

心血管医学は,心臓血管医学である.
薬理学薬理学とは
エンドクリノロジーエンドクリノロジー

背景:

ヒドロキシメチルグルタリル共酵素A還元酵素阻害剤 (スタチン) が脂質を下げない用量で内皮機能に与える短期的な効果は不明である.
内皮機能不全は,特に糖尿病患者の動脈硬化症の重要な要因です.

研究の目的:

高齢の糖尿病患者の内皮機能に対するセリバスタチンの短期効果を調査する.
窒素酸化物製品,粘着分子,酸化ストレスマーカーに対するセリバスタチンの影響を評価する.

主な方法:

27人の高齢の糖尿病患者の低用量セリバスタチン (0.15 mg/d) の3日間の治療.
内皮に依存した (フローメディエート) と独立した (ニトログリセリン) 血管拡張の評価.
酸化窒素代謝産物 (ニートリート/ニートレート,cGMP),粘着分子 (VCAM-1,ICAM-1),フォン・ウィレブランド因子,および8-イソプロスタンの測定.

主要な成果:

セリバスタチンは,フローメディエイトされた膨張を大幅に改善し,血のニートリート/ニートレートおよびcGMP濃度を増加させた.
血脂質プロファイルやニトログリセリン誘発の膨張に重大な変化は見られなかった.
プラズマの8-イソプロスタンと溶解性血管細胞粘着分子-1のレベルは低下する傾向を示した.

結論:

短期間のセリバスタチンの投与は,年配の糖尿病患者の内皮機能を向上させ,脂質低下効果とは無関係です.
観察された改善は,酸化窒素の生物学的利用可能性の増加と酸化ストレス減少に関連している可能性があります.
これらの発見は,脂質を低下させない用量でのスタチンの短期的な抗動脈硬化効果の可能性を示唆しています.

さらに関連する動画

08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

関連する概念動画

01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

関連する実験動画